Neflamapimod

CervoMed presented neflamapimod's potential in treating DLB at CTAD, highlighting significant plasma GFAP reduction (p=0.015 vs placebo) in Phase 2a trials. The ongoing RewinD-LB Phase 2b study, with 80 patients per arm, aims for nearly 100% statistical power for primary endpoint, with topline results expected in December.

Neflamapimod reduced plasma GFAP levels and improved clinical outcomes in DLB patients, with RewinD-LB Phase 2b trial enrolling DLB patients without tau pathology for optimized treatment effect evaluation.

CervoMed to present neflamapimod data for dementia with Lewy bodies (DLB) at CTAD, indicating its potential as a treatment and the importance of the RewinD-LB Phase 2b study.

At CTAD 2023, Eisai presented data showing subcutaneous lecanemab removes amyloid plaques 14% more effectively than IV, with plans to submit a biologics license application by March 31, 2024. Subcutaneous administration also showed higher pharmacokinetic AUC and similar ARIA-E rates, indicating potential for disease modification.

Recent advancements in neurology include positive phase 1/2 study results for tividenofusp alfa in Hunter syndrome, Delphi-MD for nerve stimulation, VG-3927 for Alzheimer's, and tirzepatide for sleep apnea. Ongoing trials for PGN-EDO51, tolebrutinib, and NS-050/NCNP-03 show promise. FDA discussions for CNM-Au8 and AMT-130, and approvals for Nerivio and STS101 highlight progress in treatment options.